-
1
-
-
0033812142
-
The occurrence of autoimmune diseases in patients with multiple sclerosis and their families
-
Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000; 7: 434-7.
-
(2000)
J Clin Neurosci
, vol.7
, pp. 434-437
-
-
Henderson, R.D.1
Bain, C.J.2
Pender, M.P.3
-
2
-
-
0032495663
-
Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis
-
Pender MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998; 351: 978-81.
-
(1998)
Lancet
, vol.351
, pp. 978-981
-
-
Pender, M.P.1
-
3
-
-
0031789948
-
Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis
-
Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980-3.
-
(1998)
Ann Neurol
, vol.44
, pp. 980-983
-
-
Sadatipour, B.T.1
Greer, J.M.2
Pender, M.P.3
-
5
-
-
0026496706
-
Relapsing-remitting multiple sclerosis: Sequential enhanced MR imaging v clinical findings in determining disease activity
-
Barkhof F, Scheltens P, Frequin STFM, Nauta JJ, Tas MW, Falk J et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging v clinical findings in determining disease activity. Am J Roentgenol 1992; 159: 1041-7.
-
(1992)
Am J Roentgenol
, vol.159
, pp. 1041-1047
-
-
Barkhof, F.1
Scheltens, P.2
Frequin, S.T.F.M.3
Nauta, J.J.4
Tas, M.W.5
Falk, J.6
-
6
-
-
0032576752
-
Axonal transection in the lesions of multiple sclerosis
-
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
-
(1998)
N Engl J Med
, vol.338
, pp. 278-285
-
-
Trapp, B.D.1
Peterson, J.2
Ransohoff, R.M.3
Rudick, R.4
Mork, S.5
Bo, L.6
-
7
-
-
0032796747
-
Axonal pathology in multiple sclerosis: Relationship to neurologic disability
-
Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
-
(1999)
Curr Opin Neurol
, vol.12
, pp. 295-302
-
-
Trapp, B.D.1
Ransohoff, R.2
Rudick, R.3
-
8
-
-
0035175051
-
Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis
-
Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001; 58: 57-60.
-
(2001)
Arch Neurol
, vol.58
, pp. 57-60
-
-
Leist, T.P.1
Gobbini, M.I.2
Frank, J.A.3
McFarland, H.F.4
-
9
-
-
0035166271
-
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability
-
De Stefano N, Narayanan S, Francis GS, Amaoutelis R, Tartaglia MC, Antel JP et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
-
(2001)
Arch Neurol
, vol.58
, pp. 65-70
-
-
De Stefano, N.1
Narayanan, S.2
Francis, G.S.3
Amaoutelis, R.4
Tartaglia, M.C.5
Antel, J.P.6
-
10
-
-
0033546980
-
Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
-
Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53: 751-7.
-
(1999)
Neurology
, vol.53
, pp. 751-757
-
-
Paolillo, A.1
Coles, A.J.2
Molyneux, P.D.3
Gawne-Cain, M.4
MacManus, D.5
Barker, G.J.6
-
11
-
-
0033552391
-
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
-
Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-5.
-
(1999)
Lancet
, vol.354
, pp. 1691-1695
-
-
Coles, A.J.1
Wing, M.2
Smith, S.3
Coraddu, F.4
Greer, S.5
Taylor, C.6
-
13
-
-
0028723892
-
A brief history of the use of interferons as treatment of multiple sclerosis
-
Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 1994; 51: 1245-52.
-
(1994)
Arch Neurol
, vol.51
, pp. 1245-1252
-
-
Jacobs, L.1
Johnson, K.P.2
-
14
-
-
0027418515
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
-
IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
-
(1993)
Neurology
, vol.43
, pp. 655-661
-
-
-
15
-
-
0027521002
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
-
Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
-
(1993)
Neurology
, vol.43
, pp. 662-667
-
-
Paty, D.W.1
Li, D.K.B.2
-
16
-
-
0008678962
-
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
-
The Multiple Sclerosis Collaborative Research Group
-
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. The Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
-
(1996)
Ann Neurol
, vol.39
, pp. 285-294
-
-
Jacobs, L.D.1
Cookfair, D.L.2
Rudick, R.A.3
Herndon, R.M.4
Richert, J.R.5
Salazar, A.M.6
-
17
-
-
0035954361
-
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
-
The PRISMS Study Group, the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36.
-
(2001)
Neurology
, vol.56
, pp. 1628-1636
-
-
-
18
-
-
0034727059
-
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
-
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al., the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
-
(2000)
N Engl J Med
, vol.343
, pp. 898-904
-
-
Jacobs, L.D.1
Beck, R.W.2
Simon, J.H.3
Kinkel, R.P.4
Brownscheidle, C.M.5
Murray, T.J.6
-
19
-
-
0035912520
-
Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
-
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al., the Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
-
(2001)
Lancet
, vol.357
, pp. 1576-1582
-
-
Comi, G.1
Filippi, M.2
Barkhof, F.3
Durelli, L.4
Edan, G.5
Fernandez, O.6
-
20
-
-
0033961721
-
IFN-beta differentially regulates CD40-induced cytokine secretion by human dendritic cells
-
McRae BL, Beilfuss BA, van Seventer GA. IFN-beta differentially regulates CD40-induced cytokine secretion by human dendritic cells. J Immunol 2000; 164: 23-8.
-
(2000)
J Immunol
, vol.164
, pp. 23-28
-
-
McRae, B.L.1
Beilfuss, B.A.2
Van Seventer, G.A.3
-
21
-
-
0032494792
-
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
-
European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
-
(1998)
Lancet
, vol.352
, pp. 1491-1497
-
-
-
22
-
-
0000784055
-
Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial
-
Goodkin DE, North American Study Group. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54: 2352.
-
(2000)
Neurology
, vol.54
, pp. 2352
-
-
Goodkin, D.E.1
-
23
-
-
0035849496
-
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results
-
SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504.
-
(2001)
Neurology
, vol.56
, pp. 1496-1504
-
-
-
24
-
-
0031676732
-
Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b
-
Bramanti P, Sessa E, Rifici C, D'Aleo G, Floridia D, Di Bella P et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 1998; 51: 1720-3.
-
(1998)
Neurology
, vol.51
, pp. 1720-1723
-
-
Bramanti, P.1
Sessa, E.2
Rifici, C.3
D'Aleo, G.4
Floridia, D.5
Di Bella, P.6
-
25
-
-
0035912535
-
Preventing multiple sclerosis?
-
Ebers GC. Preventing multiple sclerosis? Lancet 2001; 357: 1547.
-
(2001)
Lancet
, vol.357
, pp. 1547
-
-
Ebers, G.C.1
-
26
-
-
0033153391
-
Inhibition of B cell receptor-mediated apoptosis by IFN
-
Su L, David M. Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol 1999; 162: 6317-21.
-
(1999)
J Immunol
, vol.162
, pp. 6317-6321
-
-
Su, L.1
David, M.2
-
27
-
-
0034912060
-
The use of interferon beta at the time of initial diagnosis of multiple sclerosis
-
Pender MP. The use of interferon beta at the time of initial diagnosis of multiple sclerosis. J Clin Neurosci 2001; 8: 381-2.
-
(2001)
J Clin Neurosci
, vol.8
, pp. 381-382
-
-
Pender, M.P.1
-
28
-
-
0027976744
-
Clinical toxicity of the interferons
-
Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10: 115-50.
-
(1994)
Drug Saf
, vol.10
, pp. 115-150
-
-
Vial, T.1
Descotes, J.2
-
29
-
-
0032945247
-
Autoimmune events during interferon beta-1b treatment for multiple sclerosis
-
Durelli L, Ferrero B, Oggero A, Verdun E, Bongioanni MR, Gentile E et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999; 162: 74-83.
-
(1999)
J Neurol Sci
, vol.162
, pp. 74-83
-
-
Durelli, L.1
Ferrero, B.2
Oggero, A.3
Verdun, E.4
Bongioanni, M.R.5
Gentile, E.6
-
30
-
-
0034124639
-
Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis
-
McDonald ND, Pender MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Aust NZ J Med 2000; 30: 278-9.
-
(2000)
Aust NZ J Med
, vol.30
, pp. 278-279
-
-
McDonald, N.D.1
Pender, M.P.2
-
31
-
-
0015103005
-
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
-
Teitelbaum D, Meshorer A, Hirshfeld T, Amon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971; 1: 242-8.
-
(1971)
Eur J Immunol
, vol.1
, pp. 242-248
-
-
Teitelbaum, D.1
Meshorer, A.2
Hirshfeld, T.3
Amon, R.4
Sela, M.5
-
32
-
-
0029082566
-
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
-
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al., the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
-
(1995)
Neurology
, vol.45
, pp. 1268-1276
-
-
Johnson, K.P.1
Brooks, B.R.2
Cohen, J.A.3
Ford, C.C.4
Goldstein, J.5
Lisak, R.P.6
-
33
-
-
6844254570
-
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
-
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al., the Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-8.
-
(1998)
Neurology
, vol.50
, pp. 701-708
-
-
Johnson, K.P.1
Brooks, B.R.2
Cohen, J.A.3
Ford, C.C.4
Goldstein, J.5
Lisak, R.P.6
-
34
-
-
0033842848
-
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
-
Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP et al., the Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-66.
-
(2000)
Mult Scler
, vol.6
, pp. 255-266
-
-
Johnson, K.P.1
Brooks, B.R.2
Ford, C.C.3
Goodman, A.4
Guarnaccia, J.5
Lisak, R.P.6
-
35
-
-
18344409394
-
Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MRI assessment
-
Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scarano F et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MRI assessment. Neurology 2000; 54: 813-17.
-
(2000)
Neurology
, vol.54
, pp. 813-817
-
-
Ge, Y.1
Grossman, R.I.2
Udupa, J.K.3
Fulton, J.4
Constantinescu, C.S.5
Gonzales-Scarano, F.6
-
36
-
-
0035957307
-
Mechanisms of action of glatiramer acetate in multiple sclerosis
-
Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702-8.
-
(2001)
Neurology
, vol.56
, pp. 702-708
-
-
Neuhaus, O.1
Farina, C.2
Wekerle, H.3
Hohlfeld, R.4
-
37
-
-
8044242916
-
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
-
Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-9.
-
(1997)
J Neurol
, vol.244
, pp. 153-159
-
-
Millefiorini, E.1
Gasperini, C.2
Pozzilli, C.3
D'Andrea, F.4
Bastianello, S.5
Trojano, M.6
-
38
-
-
0000793892
-
Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, randomised, observer-blind phase III trial: Clinical results and three-year follow-up
-
Hartung HP, Gonsette RE, the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomised, observer-blind phase III trial: clinical results and three-year follow-up. Neurology 1999; 52: A290.
-
(1999)
Neurology
, vol.52
-
-
Hartung, H.P.1
Gonsette, R.E.2
-
39
-
-
0000793893
-
Mitoxantrone in progressive multiple sclerosis: MRI results of the European phase III trial
-
Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP et al., the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: MRI results of the European phase III trial. Neurology 1999; 52: A495.
-
(1999)
Neurology
, vol.52
-
-
Krapf, H.1
Morrissey, S.P.2
Zenker, O.3
Zwingers, T.4
Gonsette, R.5
Hartung, H.P.6
-
40
-
-
0027504007
-
Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults
-
Aviles A, Arevila N, Diaz Maqueo JC, Gomez T, Garcia R, Nambo MJ. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 1993; 11: 275-9.
-
(1993)
Leuk Lymphoma
, vol.11
, pp. 275-279
-
-
Aviles, A.1
Arevila, N.2
Diaz Maqueo, J.C.3
Gomez, T.4
Garcia, R.5
Nambo, M.J.6
-
41
-
-
0028906384
-
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
-
Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40.
-
(1995)
Ann Neurol
, vol.37
, pp. 30-40
-
-
Goodkin, D.E.1
Rudick, R.A.2
VanderBrug Medendorp, S.3
Daughtry, M.M.4
Schwetz, K.M.5
Fischer, J.6
-
42
-
-
0025986898
-
Overview of azathioprine treatment in multiple sclerosis
-
Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5.
-
(1991)
Lancet
, vol.338
, pp. 1051-1055
-
-
Yudkin, P.L.1
Ellison, G.W.2
Ghezzi, A.3
Goodkin, D.E.4
Hughes, R.A.5
McPherson, K.6
-
43
-
-
0026317943
-
Intense immunosuppression in chronic progressive multiple sclerosis: The Kaiser study
-
Likosky WH, Fireman B, Elmore R, Eno G, Gale K, Goode GB et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 1991; 54: 1055-60.
-
(1991)
J Neurol Neurosurg Psychiatry
, vol.54
, pp. 1055-1060
-
-
Likosky, W.H.1
Fireman, B.2
Elmore, R.3
Eno, G.4
Gale, K.5
Goode, G.B.6
-
44
-
-
0025967752
-
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
-
The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6.
-
(1991)
Lancet
, vol.337
, pp. 441-446
-
-
-
45
-
-
0027196941
-
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
-
Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-18.
-
(1993)
Neurology
, vol.43
, pp. 910-918
-
-
Weiner, H.L.1
Mackin, G.A.2
Orav, E.J.3
Hafler, D.A.4
Dawson, D.M.5
LaPierre, Y.6
-
46
-
-
0023194967
-
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1: Clinical effects
-
Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1: clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-16.
-
(1987)
J Neurol Neurosurg Psychiatry
, vol.50
, pp. 511-516
-
-
Milligan, N.M.1
Newcombe, R.2
Compston, D.A.3
-
47
-
-
0031817597
-
A phase II study of IV methylprednisolone in secondary progressive multiple sclerosis
-
Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug Medendorp S, Secic M, Gogol D et al. A phase II study of IV methylprednisolone in secondary progressive multiple sclerosis. Neurology 1998; 51: 239-45.
-
(1998)
Neurology
, vol.51
, pp. 239-245
-
-
Goodkin, D.E.1
Kinkel, R.P.2
Weinstock-Guttman, B.3
VanderBrug Medendorp, S.4
Secic, M.5
Gogol, D.6
-
48
-
-
0031057970
-
Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
-
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, the Austrian Immunoglobulin in MS Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-93.
-
(1997)
Lancet
, vol.349
, pp. 589-593
-
-
Fazekas, F.1
Deisenhammer, F.2
Strasser-Fuchs, S.3
Nahler, G.4
Mamoli, B.5
-
49
-
-
0030799818
-
Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analysis of the Austrian Immunoglobulin in MS study
-
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, the Austrian Immunoglobulin in MS Study Group. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analysis of the Austrian Immunoglobulin in MS study. Mult Scler 1997; 3: 137-42.
-
(1997)
Mult Scler
, vol.3
, pp. 137-142
-
-
Fazekas, F.1
Deisenhammer, F.2
Strasser-Fuchs, S.3
Nahler, G.4
Mamoli, B.5
-
51
-
-
0034093120
-
Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy
-
Fassas A, Anagnostopoulous A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. J Clin Immunol 2000; 20: 24-30.
-
(2000)
J Clin Immunol
, vol.20
, pp. 24-30
-
-
Fassas, A.1
Anagnostopoulous, A.2
Kazis, A.3
Kapinas, K.4
Sakellari, I.5
Kimiskidis, V.6
-
52
-
-
0033786776
-
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
-
Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-75.
-
(2000)
Nat Med
, vol.6
, pp. 1167-1175
-
-
Bielekova, B.1
Goodwin, B.2
Richert, N.3
Cortese, I.4
Kondo, T.5
Afshar, G.6
-
53
-
-
0033791462
-
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
-
Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P et al., the Altered Peptide Ligand in Relapsing MS Study Group. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000; 6: 1176-82.
-
(2000)
Nat Med
, vol.6
, pp. 1176-1182
-
-
Kappos, L.1
Comi, G.2
Panitch, H.3
Oger, J.4
Antel, J.5
Conlon, P.6
-
54
-
-
0034710361
-
T cell vaccination in secondary progressive multiple sclerosis
-
Correale J, Lund B, McMillan M, Ko DY, McCarthy K, Weiner LP. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000; 107: 130-9.
-
(2000)
J Neuroimmunol
, vol.107
, pp. 130-139
-
-
Correale, J.1
Lund, B.2
McMillan, M.3
Ko, D.Y.4
McCarthy, K.5
Weiner, L.P.6
-
55
-
-
0033546663
-
The effect of anti-α4 integrin antibody on brain lesion activity in MS
-
Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP et al., the UK Antegren Study Group. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466-72.
-
(1999)
Neurology
, vol.53
, pp. 466-472
-
-
Tubridy, N.1
Behan, P.O.2
Capildeo, R.3
Chaudhuri, A.4
Forbes, R.5
Hawkins, C.P.6
-
57
-
-
0035157681
-
Apoptosis of inflammatory cells in immune control of the nervous system: Role of glia
-
Pender MP, Rist MJ. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. GLIA 2001; 36: 137-44.
-
(2001)
GLIA
, vol.36
, pp. 137-144
-
-
Pender, M.P.1
Rist, M.J.2
-
58
-
-
0033546665
-
TNF neutralization in MS
-
The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS. Neurology 1999; 53: 457-65.
-
(1999)
Neurology
, vol.53
, pp. 457-465
-
-
-
59
-
-
0342906187
-
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
-
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.
-
(2000)
Ann Neurol
, vol.47
, pp. 707-717
-
-
Lucchinetti, C.1
Bruck, W.2
Parisi, J.3
Scheithauer, B.4
Rodriguez, M.5
Lassmann, H.6
-
60
-
-
0033850863
-
B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: Roles of B cell CD95, CD95L and Bcl-2 expression
-
White CA, Nguyen KB, Pender MP. B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: roles of B cell CD95, CD95L and Bcl-2 expression. J Autoimmun 2000; 14: 195-204.
-
(2000)
J Autoimmun
, vol.14
, pp. 195-204
-
-
White, C.A.1
Nguyen, K.B.2
Pender, M.P.3
|